NCI Drug Development Workshop II (Agenda)

Agenda

Session I. Critical Considerations for Lead Optimization
Thursday, June 22, 2023
1 pm – 2:30 pm
Overview of lead optimization Steven Olson, Ph.D., Executive Director,
Medicinal Chemistry, Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute
ADMET assessment Li Di, Ph.D., Research Fellow, Dynamics, and Metabolism Department, Pfizer
Session II. Considerations for Advancing to Late Preclinical Development
Friday, June 23, 2023
1 pm – 2:30 pm
Criteria for an SM entering IND-enabling studies Li Di, Ph.D., Research Fellow, Dynamics, and Metabolism Department, Pfizer
Elizabeth Glaze, Ph.D., Chief, Toxicology and Pharmacology Branch, Developmental Therapeutics Program, National Cancer Institute
Development of pharmacodynamic biomarkers Apurva Srivastava, Ph.D., DABCC, Senior Principal Scientist at Leidos Biomedical Research, INC.
Session III. Safety and Toxicity Studies for Small Molecules
Thursday, July 13, 2023
1 pm – 2 pm
Safety and toxicity studies for small molecules Elizabeth Glaze, Ph.D., Chief, Toxicology and Pharmacology Branch, Developmental Therapeutics Program, National Cancer Institute
Session IV. Formulation of Small Molecules
Friday, July 14, 2023
1 pm – 2:30 pm
Formulation considerations during lead optimization Huan Xie, Ph.D., Professor, Department of Pharmaceutical Science, Texas Southern University
Formulation studies for clinical candidates Jing Ling, Ph.D., Associate Principle Scientist, Discovery Pharmaceutical Sciences, Merck
Session V. Nanoparticle Delivery of Cancer Drugs
Thursday, July 27, 2023
1 pm – 2:30 pm
Overview and nanoparticle characterization Stephan Stern, Ph.D., DABT Laboratory Co-Director, Director of Research and Development, and Head of the pharmacology and toxicology section of the Nanotechnology Characterization Laboratory, Frederick National Laboratory for Cancer Research
FDA regulatory considerations for nanomedicines Wimolnut Manheng, Ph.D., DABT, Toxicologist, Center for Drug Evaluation and Research, Food and Drug Administration
Session VI: Good-to-know IP Knowledge
Friday, July 28, 2023
1 pm – 2 pm
Good-to-know IP Knowledge Jason Cristofaro, Ph.D., J.D., Intellectual Property Program Manager, Division of Cancer Treatment and Diagnosis, National Cancer Institute